This page has only limited features, please log in for full access.
Diabetes mellitus (DM) represents an independent risk factor for chronic AF and is associated with unfavorable outcomes. We aimed to evaluate the efficacy and safety of direct oral anticoagulants (DOACs) in patients with atrial fibrillation (AF), with and without diabetes mellitus (DM), using a new risk index (RI) defined as: RI
Domenico Acanfora; Marco Ciccone; Valentina Carlomagno; Pietro Scicchitano; Chiara Acanfora; Alessandro Bortone; Massimo Uguccioni; Gerardo Casucci. A Systematic Review of the Efficacy and Safety of Direct Oral Anticoagulants in Atrial Fibrillation Patients with Diabetes Using a Risk Index. Journal of Clinical Medicine 2021, 10, 2924 .
AMA StyleDomenico Acanfora, Marco Ciccone, Valentina Carlomagno, Pietro Scicchitano, Chiara Acanfora, Alessandro Bortone, Massimo Uguccioni, Gerardo Casucci. A Systematic Review of the Efficacy and Safety of Direct Oral Anticoagulants in Atrial Fibrillation Patients with Diabetes Using a Risk Index. Journal of Clinical Medicine. 2021; 10 (13):2924.
Chicago/Turabian StyleDomenico Acanfora; Marco Ciccone; Valentina Carlomagno; Pietro Scicchitano; Chiara Acanfora; Alessandro Bortone; Massimo Uguccioni; Gerardo Casucci. 2021. "A Systematic Review of the Efficacy and Safety of Direct Oral Anticoagulants in Atrial Fibrillation Patients with Diabetes Using a Risk Index." Journal of Clinical Medicine 10, no. 13: 2924.
In recent weeks, adverse reactions have been reported after administration of Oxford–AstraZeneca chimpanzee adenovirus vectored vaccine ChAdOx1 nCoV-19 (AZD1222), in particular thrombus formation, which has led several European Countries to discontinue administration of this vaccine. On March 8, 2021, the European Medicines Agency Safety Committee did not confirm this probable association. We report the case of a patient who developed disseminated intravascular coagulation after the first dose of Oxford-Astra Zeneca vaccine, which resolved in a few days with the administration of dexamethasone and enoxaparin. This work demonstrates the safety of the Oxford-Astra Zeneca vaccine and that any development of side effects can be easily managed with a prompt diagnosis and in a short time with a few commonly used drugs.
Gerardo Casucci; Domenico Acanfora. DIC-Like Syndrome Following Administration of ChAdOx1 nCov-19 Vaccination. Viruses 2021, 13, 1046 .
AMA StyleGerardo Casucci, Domenico Acanfora. DIC-Like Syndrome Following Administration of ChAdOx1 nCov-19 Vaccination. Viruses. 2021; 13 (6):1046.
Chicago/Turabian StyleGerardo Casucci; Domenico Acanfora. 2021. "DIC-Like Syndrome Following Administration of ChAdOx1 nCov-19 Vaccination." Viruses 13, no. 6: 1046.
This paper presents a brief overview of the complex interaction between age, hypertension, the renin–angiotensin–aldosterone system (RAAS), inflammation, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection. Coronavirus disease 2019 (COVID-19) is more frequent and more severe in comorbid elderly patients, especially those with hypertension, diabetes, obesity, or cardiovascular diseases. There are concerns regarding the use of RAAS inhibitors in patients with COVID-19. Some physicians have considered the need for interrupting RAAS inhibition in order to reduce the possibility of SARS-CoV2 entering lung cells after binding to angiotensin-converting enzyme 2 (ACE2) receptors. We offer a different point of view in relation to the need for continuing to use RAAS inhibitors in patients with COVID-19. We focused our article on elderly patients because of the distinctive imbalance between the immune response, which is depressed, and the exacerbated inflammatory response, ‘inflammaging’, which makes the geriatric patient an appropriate candidate for therapeutic strategies aimed at modulating the inflammatory response. Indeed, COVID-19 is an inflammatory storm that starts and worsens during the course of the disease. During the COVID-19 pandemic, various therapeutic approaches have been tested, including antiviral drugs, interferon, anti-interleukins, hydroxychloroquine, anti-inflammatories, immunoglobulins from recovered patients, and heparins. Some of these therapeutic approaches did not prove to be beneficial, or even induced serious complications. Based on current evidence, in the early stages of the disease modulation of the inflammatory response through the inhibition of neprilysin and modulation of the RAAS could affect the course and outcome of COVID-19.
Gerardo Casucci; Domenico Acanfora; Raffaele Antonelli Incalzi. The Cross-Talk between Age, Hypertension and Inflammation in COVID-19 Patients: Therapeutic Targets. Drugs & Aging 2020, 37, 779 -785.
AMA StyleGerardo Casucci, Domenico Acanfora, Raffaele Antonelli Incalzi. The Cross-Talk between Age, Hypertension and Inflammation in COVID-19 Patients: Therapeutic Targets. Drugs & Aging. 2020; 37 (11):779-785.
Chicago/Turabian StyleGerardo Casucci; Domenico Acanfora; Raffaele Antonelli Incalzi. 2020. "The Cross-Talk between Age, Hypertension and Inflammation in COVID-19 Patients: Therapeutic Targets." Drugs & Aging 37, no. 11: 779-785.